By Katherine Hamilton
Kazia Therapeutics stock retreated Tuesday after the FDA said it could consider standard, but not accelerated, approval for the company's brain cancer drug.
Shares of the oncology-focused drug company fell 26% to $2.28 in morning trading. The stock is down about 48% this year.
The drug, called paxalisib, is designed to treat the brain cancer glioblastoma. It showed clinically meaningful improvement in overall survival during a July trial, and Kazia's stock more than quadrupled.
The FDA said it would generally not approve accelerated approval for pazalisib, Kazia said Tuesday. It could consider support for a standard approval.
The FDA said some of the overall survival data would be supportive for designing a pivotal registrational study to pursue standard approval. The agency agreed with Kazia on aspects of a phase 3 study, including patient population and primary endpoint, Kazia said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
December 31, 2024 10:11 ET (15:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.